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 Abstract 
Despite the critical need, no previous research has substantiated safe opioid analgesics without abuse liability in 
primates. Recent advances in medicinal chemistry have led to the development of ligands with mixed mu opioid 
peptide (MOP)/nociceptin-orphanin FQ peptide (NOP) receptor agonist activity to achieve this objective. BU08028 
is a novel orvinol analog that displays a similar binding profile to buprenorphine with improved affinity and efficacy 
at NOP receptors. The aim of this preclinical study was to establish the functional profile of BU08028 in monkeys 
using clinically used MOP receptor agonists for side-by-side comparisons in various wellhoned behavioral and 
physiological assays. Systemic BU08028 (0.001–0.01 mg/kg) produced potent long-lasting (i.e., >24 h) 
antinociceptive and antiallodynic effects, which were blocked by MOP or NOP receptor antagonists. More 
importantly, the reinforcing strength of BU08028 was significantly lower than that of cocaine, remifentanil, or 
buprenorphine in monkeys responding under a progressive-ratio schedule of drug self-administration. Unlike MOP 
receptor agonists, BU08028 at antinociceptive doses and ∼10to 30-fold higher doses did not cause respiratory 
depression or cardiovascular adverse events as measured by telemetry devices. After repeated administration, the 
monkeys developed acute physical dependence on morphine, as manifested by precipitated withdrawal signs, such 
as increased respiratory rate, heart rate, and blood pressure. In contrast, monkeys did not show physical dependence 
on BU08028. These in vivo findings in primates not only document the efficacy and tolerability profile of 
bifunctional MOP/NOP receptor agonists, but also provide a means of translating such ligands into therapies as safe 
and potentially abuse free opioid analgesics. 
N/OFQ peptide receptor | respiratory depression | reinforcing effects | physical dependence | mu opioid peptide 
receptor 
 
 
Significance 
A potent opioid analgesic without addictive and respiratory adverse effects has been a predominant goal for opioid 
medicinal chemistry since the isolation of morphine from opium in the 19th century. Here we report a functional 
profile of a unique analog, BU08028, targeting a combination of a classical and nonclassical opioid receptors in 
monkeys. By examining behavioral, physiological, and pharmacologic factors, the present study demonstrates that 
BU08028 exhibits full antinociception and antihypersensitivity without reinforcing effects (i.e., abuse liability), 
respiratory depression, pruritus, adverse cardiovascular events, or acute physical dependence. Because monkey 
models provide the most phylogenetically appropriate evaluation of opioid receptor functions and drug effects, 
these findings provide a translational bridge for such ligands as effective analgesics without safety and abuse 
liability concerns. 
 
  
Introduction 
Pain, a symptom of numerous clinical disorders, afflicts millions of people worldwide. Despite the remarkable 
advances in the identification of potential targets as analgesics in the last decade, mu opioid peptide (MOP) receptor 
agonists remain the most widely used analgesics for pain management (1). Several side effects associated with MOP 
receptor agonists have severely limited the value of opioid analgesics, however (2). Owing to the abuse liability and 
the high mortality rate caused by respiratory arrest, opioid abuse not only has dire consequences, but also leads to 
mounting medical and economic burdens in our society (3–5). There is a clear, unmet need for safe analgesics without 
abuse liability in the global community. 
 
Buprenorphine, a partial MOP receptor agonist, is considered a safe analgesic because of its ceiling effect on 
respiratory depression (6, 7). Buprenorphine is commonly used in both human and veterinary medicine to treat 
various pain conditions, including cancer pain and neuropathic pain (7, 8). However, buprenorphine is not devoid of 
reinforcing effects, the most devastating side effect of MOP receptor agonists. The abuse or misuse of buprenorphine 
has been documented, which limits its use worldwide (9–11). There has been a decades-long effort aimed at 
developing opioid analgesics with fewer side effects (12–15), but to date, safe opioid analgesics devoid of abuse 
potential remain undiscovered (16, 17). 
Recent research on the nociceptin/orphanin FQ peptide (NOP) receptor could open an avenue for developing new 
analgesics. (17–20). Following spinal and systemic administration, NOP receptor agonists produce antinociception 
and antihypersensitivity comparable to those of MOP receptor agonists, but without reinforcing effects in nonhuman 
primates (21–24). More importantly, NOP agonists interact with buprenorphine in a synergistic manner to produce 
antinociceptive effects (25). Simultaneous activation of both NOP and MOP receptors to a small degree may 
produce desirable analgesic effects with fewer side effects—that is, a wider therapeutic window (17). Given that 
NOP receptor agonists have no abuse liability and/or can block or decrease the reinforcing effects of MOP receptor 
agonists (26–29), it is worth developing bifunctional MOP/NOP receptor agonists as potentially non-addictive 
analgesics. 
 
Several medicinal chemistry groups have discovered such agonists with varying affinity and efficacy at MOP and 
NOP receptors (30–33). Subsequent to chemical modifications, some of these ligands exhibited antinociceptive and 
antihypersensitive efficacy with improved potency across different rodent pain models (31, 34–36). However, in 
vivo functional profiles of these ligands in primates are completely unknown. Among these recently developed 
ligands, BU08028 emerged from the orvinol series and displays a similar receptor binding profile to buprenorphine, 
but with better binding affinity (Ki, ∼8 nM) and efficacy (∼48% stimulation of [35S]GTPγS binding) on NOP 
receptors (37, 38). Therefore, BU08028 appears to be an ideal pharmacologic agent with mixed MOP/NOP agonist 
activity that merits further study. 
Numerous studies have documented differences in the pharmacologic actions of MOP-related ligands (15, 39, 40) 
and NOPrelated ligands (24, 41, 42) between rodents and nonhuman primates. In particular, the abuse liability and 
respiratory depression of MOP receptor agonists in humans can be most closely simulated in monkeys (43–45). 
Thus, it is extremely valuable to conduct functional studies in awake, behaving monkeys as a preclinical framework 
to validate the therapeutic profile of BU08028, and also to establish a translational bridge for the bifunctional MOP/ 
NOP receptor agonists in humans. In the present study, we conducted large-scale experiments using various well-
established behavioral and physiological assays to provide a comprehensive pharmacologic profile of BU08028 in 
nonhuman primates. Using prototypical MOP receptor agonists for comparison, we investigated the characteristics 
of BU08028 as an analgesic and its reinforcing effects and physiological functions, including pruritus, respiration, 
and cardiovascular activities. In addition, we applied a short-term repeated-dosing regimen to evaluate the 
development of acute physical dependence on BU08028. 
 
Results 
BU08028 Produces Potent and Long-Lasting Antinociceptive and Antiallodynic Effects. After s.c. 
administration, BU08028 produced antinociceptive effects against an acute noxious stimulus, 50 °C water, in a dose-
dependent [F(3, 9) = 72.3; P < 0.05] and timedependent [F(9, 27) = 16.1; P < 0.05] manner (Fig. 1A). The minimum 
effective dose of BU08028 to produce full antinociception was 0.01 mg/kg. The duration of action produced by this 
dose was 30 h, and it subsided by 48 h. To determine the antihypersensitive efficacy of BU08028, we used a clinically 
relevant model, capsaicininduced allodynia, which has been widely applied to evaluate analgesics in humans (46, 
47). Systemic BU08028 attenuated capsaicin-induced thermal allodynia in 46 °C water both dosedependently [F(3, 
9) = 360.8; P < 0.05] and time-dependently [F(3, 9) = 42.2; P < 0.05] (Fig. 1B). 
 
We next conducted antagonist studies using a MOP receptorselective dose of the opioid receptor antagonist 
naltrexone and the selective NOP receptor antagonist J-113397 (21, 23). Pretreatment with a single dose of 
naltrexone (0.03 mg/kg) or J-113397 (0.1 mg/kg) produced similar degrees (dose ratios approximately threefold) of 
the rightward shift of the dose–response curve for BU08028-induced antinociception (Fig. 1C). These findings 
indicate that MOP and NOP receptors contributed equally to the antinociceptive effects of BU08028. Using the same 
group of subjects, we further compared the potency and duration of action of BU08028 and buprenorphine. Based 
on the dose–response curves, systemic BU08028 was more potent than buprenorphine (ED50 = 0.003 mg/kg vs. 0.03 
mg/kg) (Fig. 1D), and the antinociceptive duration of BU08028 0.01 mg/kg was much longer than that of 
buprenorphine 0.1 mg/kg (>24 h vs. 1–6 h) (Fig. 1E). 
 
To examine whether BU08028 elicits itch sensation, we compared its effects with the MOP receptor agonist fentanyl, 
which was previously shown to elicit scratching responses in monkeys (48). Although BU08028 0.01 mg/kg 
produced potent and long-lasting antinociceptive and antihypersensitive effects, it did not significantly increase 
scratching responses [F(1, 3) = 4.5; P = 0.1]. In contrast, fentanyl 0.018 mg/kg elicited scratching responses in a 
timedependent manner in the same subjects [F(1, 3) = 15.4; P < 0.05] (Fig. 1F). These findings strongly indicate that 
systemic BU08028 has a promising analgesic profile in primates. 
 
BU08028 Does Not Have Reinforcing Effects. To examine and compare the reinforcing strengths of drugs, we used 
a progressive-ratio (PR) schedule of reinforcement that has been commonly used for evaluating abuse potential (49–
51). For these studies, monkeys were trained to self-administer cocaine and various doses of the MOP receptor 
agonists remifentanil and buprenorphine, as well as BU08028. For all monkeys, substitution of saline for the 
maintenance dose of cocaine (0.03 mg/kg per injection) resulted in a low number of reinforcers (three or fewer 
injections) within approximately five sessions. There was a main effect of dose for remifentanil 
[F(4,12) = 21.8; P < 0.05] and buprenorphine [F(4,12) = 8.9; P < 0.05], but not for BU08028. Several doses of 
remifentanil and buprenorphine functioned as reinforcers (Fig. 2A). One-way ANOVA revealed an expected 
difference in peak reinforcers delivered across drugs [F(3,9) = 28.9; P < 0.05]. The peak number of reinforcers for 
remifentanil and buprenorphine differed significantly from each other, as well as from saline and BU08028. The 
peak numbers of self-administered injections of saline and BU08028 were not different (Fig. 2B). Overall, the 
reinforcing strength of BU08028 was significantly lower than that of cocaine, remifentanil, and buprenorphine and 
no different from that of saline. 
 
Higher Doses of BU08028 Do Not Compromise Physiological Functions. To characterize the safety profile of 
BU08028, we implanted radiotelemetric transmitters in monkeys for real-time measurements of different 
physiological functions (52). A systemic dose (0.01 mg/kg) of BU08028 that produced full antinociceptive effects 
did not significantly affect the respiratory function of freely moving monkeys, i.e., no respiratory depression (Fig. 3 
A–E). More importantly, at a dose (0.1 mg/kg) that is ∼10–30 times higher than its antinociceptive doses (0.003–0.01 
mg/kg), BU08028 did not cause any significant decreases across various respiratory parameters including respiratory 
rate, minute volume, tidal volume, peak inspiratory and expiratory flow (all F values 0.3–3; P > 0.1) during the 48-h 
observation period (Fig. 3 A–E). In stark contrast, an antinociceptive dose of fentanyl (0.056 mg/kg) (53) rapidly 
caused respiratory depression in a single monkey, which was reversed by a MOP receptor antagonist naltrexone (Fig. 
3A, Inset). For safety reasons, this particular experiment was conducted in only one monkey. In addition, neither 
dose of BU08028 caused bradycardia or hypotension (Fig. 4 A and D). By examining various electrocardiography 
(ECG) parameters, we found that neither dose of BU08028 significantly changed any cardiovascular measures. 
Herein we show the ECG parameters such as QRS, ST-E, and pulse height, and the body temperature remained 
unchanged in monkeys receiving 0.1 mg/kg of BU08028 (Fig. 4 B, C, E, and F) (all F values 0.2–2; P > 0.3). These 
findings clearly illustrate that unlike standard MOP receptor agonists, BU08028 is a safe analgesic in primates. 
Repeated Administration of BU08028 Does Not Produce Acute Physical Dependence. Following repeated 
exposure to antinociceptive doses of MOP receptor agonists, monkeys quickly develop acute physical dependence, 
as revealed by the emergence of withdrawal signs after administration of an opioid receptor antagonist (40, 54). 
Using similar repeated-dosing regimens, we compared the development of physical dependence on the MOP receptor 
agonist morphine, the NOP receptor agonist SCH221510, and the mixed MOP/NOP agonist BU08028 in the same 
subjects. Antagonistprecipitated withdrawal signs were measured in monkeys implanted with the telemetric device 
described above. 
 
Compared with the vehicle-treated condition (0.1 mL/kg twice daily for 3 d), naltrexone (0.01 mg/kg) precipitated 
withdrawal signs on day 4 in morphine-treated (1.8 mg/kg twice daily for 3 d) monkeys. These withdrawal signs 
were manifested by increases in respiratory rate [F(1, 3) = 18.1; P < 0.05], minute volume [F(1, 3) = 124.3; P < 0.05], 
heart rate [F(1, 3) = 17.3; P < 0.05], and mean arterial pressure [F(1, 3) = 24.9; P < 0.05] without changes in body 
temperature [F(1, 3) = 0.4; P > 0.5] (Fig. 5 A–E). For a side-by-side comparison, following repeated administration 
of SCH221510 (0.01 mg/kg twice daily for 3 d), J-113397 (0.03 mg/kg) did not precipitate withdrawal signs, with 
no changes in all physiological parameters detected (all F values 0.02–0.8; P > 0.4) (Fig. 5 F–J). More importantly, 
after repeated administration of BU08028 (0.01 mg/kg once daily for 3 d), the combination of naltrexone and J-
113397 at the same doses did not precipitate withdrawal signs (all F values 0.4–2.5; P > 0.1) (Fig. 5 K–O). Taken 
together, the foregoing findings indicate that, unlike morphine, selective NOP receptor agonist SCH221510 and 
bifunctional MOP/NOP receptor agonist BU08028 do not produce acute physical dependence following 3 d of 
repeated administration. 
 
Discussion 
This first-in-primate study demonstrates that an orvinol analog (BU08028) with mixed MOP/NOP agonist activity 
displays a promising efficacy and tolerability profile as an analgesic following acute and repeated administration. 
The study provides four significant findings with direct translational impact on the development of safe opioid 
analgesics without abuse liability. First, BU08028 is highly potent, producing long-lasting antinociceptive and 
antihypersensitive actions mediated by both MOP and NOP receptors. Second, BU08028 does not have reinforcing 
effects under conditions in which other drugs with known abuse liability in the global community (including 
cocaine, remifentanil, and buprenorphine) function as reinforcers. Third, unlike the MOP receptor agonist fentanyl, 
BU08028 is safe and does not inhibit respiratory and cardiovascular activities at or above analgesic doses. Fourth, 
unlike the commonly used opioid analgesic morphine, repeated administration of BU08028 does not produce acute 
physical dependence. 
 
BU08028 exhibits an extra-long duration of antinociceptive and antiallodynic actions, up to 30 h. To our knowledge, 
this is the sole analgesic with such a long duration of action in nonhuman primates. The high logP value of BU08028 
could contribute to its unique pharmacokinetic profile (30, 38). More interestingly, antagonist studies have 
demonstrated that both MOP and NOP receptors contribute to BU08028-induced antinociception in primates. This 
is in contrast to rodent studies showing that pretreatment with a NOP receptor antagonist potentiated 
BU08028induced antinociception (38). Nonetheless, the functional profile of BU08028 in monkeys provides proof 
of concept that a single molecule with mixed MOP and NOP agonist activity is more potent than selective ligands 
and devoid of MOP receptor-mediated side effects (17, 25). 
On the other hand, capsaicin-induced allodynia has significant value in studying pain mechanisms and 
pharmacologic interventions in humans (46, 47). Given that capsaicin-sensitive nerve fibers are involved in a variety 
of pain conditions, the full effectiveness of BU08028 in inhibiting capsaicin-induced allodynia may indicate its 
clinically relevant analgesic efficacy. In addition, rodent studies have demonstrated the analgesic efficacy of NOP-
related agonists across diverse pain modalities, including inflammatory pain, neuropathic pain, and sickle cell pain 
(18, 20, 22, 29). Cumulative evidence supports a broad application of NOP-related agonists as analgesics. 
In dramatic contrast to cocaine, remifentanil, and buprenorphine, BU08028 does not possess detectable reinforcing 
strength when self-administration is studied under a PR schedule of reinforcement. Under a PR schedule, the 
response requirement for delivery of each reinforcer is successively increased. PR schedules measure how many 
responses subjects will emit to receive a drug injection before they cease to respond. The value of this schedule for 
assessing abuse liability is that it can provide an empirical differentiation among drugs that function as positive 
reinforcers (49–51). Remifentanil and buprenorphine exhibit strong and mildto-moderate reinforcing strengths, 
respectively, in monkeys under the PR schedule, concordant with their abuse potential in humans (4, 9). 
 
The present study also distinguishes between remifentanil and buprenorphine in terms of reinforcing strength. The 
lack of reinforcing effects of BU08028 under the same PR schedule as the other three drugs clearly suggests that this 
drug has lower abuse potential than buprenorphine in humans. Considering that the peak reinforcing strength of 
BU08028 does not differ from that of saline, the results go a step further to suggest that BU08028 has zero abuse 
potential. Given the decades-long effort aimed at developing abuse-free opioid analgesics (16, 17), BU08028 
represents a major breakthrough for opioid medicinal chemistry. 
 
Opioid analgesics are often associated with compromised physiological functions, particularly respiratory 
depression, which directly relates to mortality rates for pain management and overdose in addicted persons (4, 5, 
55). The present study investigated the acute effects of BU08028 on physiological functions by measuring both 
respiratory and cardiovascular parameters simultaneously in the same group of freely moving monkeys implanted 
with a radiotelemetry device. Impedance-based measurement of respiratory function has been extensively described 
in humans, and the approach of combined cardiopulmonary assessments has been validated in monkeys (56). The 
basal values of these physiological parameters in this study are in line with those reported in rhesus monkeys (40, 
52, 54). BU08028 at antinociceptive doses and ∼10- to 30-fold higher doses did not cause significantly respiratory 
depression or adverse cardiovascular events, whereas fentanyl produced a rapid, severe decrease in respiratory rate. 
Of note, a buprenorphine-like agonist, BU72, displayed a wide therapeutic window in mice, but its safety 
pharmacology profile could not be translated to primates owing to its respiratory depressant effects (15). BU08028 
represents a safe opioid analgesic with a much wider therapeutic window than that of MOP receptor agonists. 
 
Acute physical dependence occurs after fairly short-term (i.e., 1–3 d) administration of opioids in monkeys and 
humans (40, 54, 57). With precipitated withdrawal, distinctive withdrawal signs can be detected by administration 
of a cognate receptor antagonist. Using the same telemetry device, we found that administration of naltrexone 
significantly increased respiratory rate, minute volume, heart rate, and blood pressure in morphine-treated monkeys. 
These findings are consistent with previous studies demonstrating the development of acute physical dependence on 
morphine in nonhuman primates (40, 54), and validate respiratory and cardiovascular parameters as reliable and 
quantitative indicators of antagonist precipitated withdrawal. More importantly, under the same repeated dosing 
regimen with doses producing full antinociception, neither the NOP receptor agonist SCH221510 nor BU08028 
produced acute physical dependence. These results further support the notion that unlike MOP receptor agonists, 
NOP-related agonists have less liability to develop physical dependence following a short-term exposure. 
In the context of chronic pain management, development of opioid analgesic tolerance occurs and is attributed to 
several factors, including aggravation of pain, neuroadaptation of MOP receptors, and opioid-induced hyperalgesia 
(3, 4, 58). Owing to ethical concerns, there is no chronic pain model in nonhuman primates. Nonetheless, repeated 
intrathecal or i.p. administration of drugs with dual MOP/NOP receptor agonist activity (e.g., SR16435, 
cebranopadol) was found to result in slower development of tolerance to their antiallodynic effects compared with 
MOP agonists in rodents under neuropathic pain (35, 36). Morphine and buprenorphine have different analgesic 
potencies and tolerance development in humans, with a faster onset of tolerance to morphine (6, 59). Based on well-
justified doses and duration of action, future studies will further determine whether chronic administration of 
BU08028 has a slower development of tolerance to its antinociceptive effects compared with morphine and 
buprenorphine in nonhuman primates. 
 
To our knowledge, the present study provides the first functional evidence in nonhuman primates that BU08028 with 
mixed MOP/NOP agonist activities is an effective and safe analgesic without apparent abuse liability or other opioid-
associated side effects. These in vivo findings strongly support the hypothesis that coactivation of MOP and NOP 
receptors can widen the therapeutic window through their synergistic interactions (17). In recent years, medicinal 
chemists have developed bifunctional MOP/NOP receptor agonists with a wide range of efficacies (i.e., from low to 
moderate to full efficacy) (19, 29, 30, 33). Because ligands with differential intrinsic efficacies for activating MOP 
and NOP receptors have distinct integrated functional outcomes, it is essential that their efficacy and tolerability 
profiles (e.g., abuse liability, respiratory depression, physical dependence) be studied in awake, behaving monkeys. 
Such pharmacologic studies not only will validate the therapeutic profiles of bifunctional MOP/NOP receptor 
agonists, but also will translate candidate drugs into therapies as safe, abuse-free analgesics that are long overdue in 
the global community. 
 
Materials and Methods 
Animals. All animal care and experimental procedures were conducted in accordance with the National Institutes of 
Health’s Guide for the Care and Use of Laboratory Animals and approved by Wake Forest University’s Institutional 
Animal Care and Use Committee. This study is reported in accordance with the ARRIVE (Animal Research: 
Reporting of In Vivo Experiments) guidelines for reporting experiments involving animals (60). Twelve adult male 
and female rhesus monkeys (Macaca mulatta), age 10–17 y and weight 6.5–13 kg, were kept at an indoor facility 
accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Animals 
were housed individually in species-specific rooms with environmental controls set to maintain 21–25 °C, 40–60% 
relative humidity, and a 12-h light (06:30–18:30)/ 12-h dark cycle. The daily diet consisted of ∼20–28 biscuits 
(Purina Monkey Chow; Ralston Purina) and fresh fruit and water ad libitum. Small amounts of nonhuman primate 
treats and various cage-enrichment devices were supplied as forms of environmental enrichment. Animals were not 
exposed to any opioid compound for 1 mo before the present study. 
Nociceptive Responses. 
Acute thermal nociception. The warm water tail-withdrawal assay was used to evaluate thermal antinociceptive 
effects of BU08028 and MOP receptor agonists (21). Monkeys were seated in primate restraint chairs in a designated 
procedure room, and the lower parts of their shaved tails (∼15 cm) were immersed in a thermal flask containing 
water maintained at 42, 46, or 50 °C. Water at 42 and 46 °C was used as nonnoxious stimuli, and water at 50 °C 
served as an acute noxious stimulus. All tail-withdrawal latencies were measured at each temperature using a 
computerized timer by investigators who were unaware of the experimental conditions. If a monkey did not remove 
its tail within 20 s (cutoff), the flask was removed, and a maximum time of 20 s was recorded. 
 
Test sessions began with baseline measurements at each temperature. Subsequent tail-withdrawal latencies were 
measured at multiple time points after s.c. administration of a single dose of test compound. For dose–response 
curves, the test compound was administered by a cumulative dosing procedure with a 30-min interinjection interval. 
Tail-withdrawal latencies were measured at 20 min after each injection. A single dose of MOP receptor-selective 
antagonist naltrexone (0.03 mg/kg) or NOP receptor-selective antagonist J-113397 (0.1 mg/kg) was administered 
s.c. at 15 min before determination of dose– response curves to compare their antagonist effects against BU08028-
induced antinociception. The doses and pretreatment time for both naltrexone and J-113397 were chosen based on 
previous studies (23, 25). 
Capsaicin-induced thermal allodynia. At multiple time points after s.c. administration of BU08028,0.3mLofcapsaicin 
at1.2 mg/mL was administeredtopically via a bandage attached on the terminal 3–5 cm of the tail for 15 min (61). 
The allodynic effects of capsaicin peak at 15 min after removal of the capsaicin bandage, and this is the time at which 
to measure the tail-withdrawal latency in 46 °C water to evaluate the antiallodynic effects of the test compound. This 
allodynic response was manifested as reduced tail-withdrawal latency from a maximum value of 20 s to ∼2–3 s in 
46 °C water (21, 61). 
Itch Scratching Responses. The monkeys’ behaviors were recorded in their home cages for scratching activity, which 
has been associated previously with itch sensation (48). Each 15-min recording session was conducted at multiple 
time points after s.c. administration of BU08028 or fentanyl. A scratch was defined as one brief (<1 s) episode of 
scraping contact of the forepaw or hindpaw on the skin surface. Total scratches were counted and summed for each 
15-min time block by experimenters who were unaware of the experimental conditions. 
Drug Self-Administration. Four monkeys with indwelling i.v. catheters and s.c. vascular access ports were used. 
Monkeys had been trained previously to selfadminister (−)cocaine HCl (National Institute on Drug Abuse) under a 
PR schedule of reinforcement in sessions that started at ∼3:00 PM each day. Before each session, the pump was 
operated for ∼30 s to fill the catheter with the drug solution available for that session. Under the PR schedule, white 
lights were illuminated above the right lever and 50 responses resulted in a 10-s injection, extinguishing of white 
lights and illumination of red lights for 10 s. During a 10-min timeout period, no lights were illuminated and 
responding had no scheduled consequences. The response requirement for subsequent injections was determined by 
the exponential equation used by Richardson and Roberts (1996), ratio = [5 × e(R × 0.2)] – 5, where e is the mathematical 
constant and R is equal to the reinforcer number. 
 
For the present study, the first response requirement (50 responses) corresponds to the 12th value given by this 
equation and was followed by 62, 77, 95,117,144,177,218,267,328,402,492,602,737,901,1,102,1,347,etc.Sessions 
ended when 2 h elapsed without an injection. Initially, the monkeys’ responding was maintained by injections of 
0.03 mg/kg cocaine until responding was stable (mean ± three injections for three consecutive sessions with no 
trend). Next, dose-effect curves were determined in each monkey by substituting saline and a range of doses of 
remifentanil (0.03‒1 μg/kg per injection), buprenorphine (1‒30 μg/kg per injection) or BU08028 (0.3‒30 μg/kg per 
injection) for the maintenance dose in a quasi-random order. Doses were available for at least five consecutive 
sessions and until responding was deemed stable. The dependent variable of primary interest was the number of drug 
injections earned under the PR schedule. The order of testing was remifentanil, buprenorphine, and BU08028. 
Surgical Implantation of Telemetry Device. Before surgery, animals were given atropine (0.04 mg/kg s.c.), 
buprenorphine (0.01–0.03 mg/kg i.m.), and cefotaxime (500 mg i.v.) for pain management and to prevent 
inflammation and infection. The animals were then anesthetized with ketamine (10 mg/kg i.m.), and a catheter was 
placed in a saphenous vein for administration of lactated Ringer’s solution during the surgery. The animals were 
intubated and maintained under anesthesia with inhaled isoflurane or sevoflurane (1– 2% in 1 L/min O2). The animals 
were placed in dorsal recumbency for surgery. The surgical sites were prepared for strict aseptic surgery by cleansing 
with povidone-iodine, followed by 70% isopropyl alcohol. Vital signs, including heart rate, respiration rate, indirect 
blood pressure, and body temperature, were monitored during the surgery and in the immediate postoperative 
recovery period. The animals received buprenorphine (0.003– 0.02 mg/kg i.m.) and meloxicam (0.15 mg/kg s.c.) as 
postoperative analgesics and ceftiofur (2.2 mg/kg i.m.) as the postoperative antibiotic. Postoperative care and 
incision site observations were performed daily for 14 d or until healing was complete. 
 
A cardiopulmonary telemetry transmitter [model TL11M3-D70-PCTR; Data Sciences International (DSI)] was 
surgically implanted into each of four monkeys. This transmitter device was placed between the internal and external 
abdominal loblique muscles on the flank, and the green ground lead wasplaced intramuscularly near the device body. 
The blood pressure catheter was inserted into the femoral artery with the pressure-sensing tip in the aorta. The 
positive ECG lead was placed on the abdominal side of the diaphragm near the apex of the left ventricle. The solid-
tip negative ECG lead was placed into the cranial vena cava via the right internal jugular vein. The final depth of 
positioning was determined based on optimization of a live telemetry signal. Two respiratory impedance leads were 
placed intramuscularly on each side of the chest along the transverse plane of the seventh rib. Both negative leads 
(white stripes) were placed on the right side of the chest, and both positive leads (solid colors) were placed on the 
left side. The violet leads were placed cranial to the seventh rib, and the turquoise leads were placed caudal to the 
seventh rib. All of the leads were cut to the appropriate length. The insulation was removed, and the exposed wire 
was looped and secured with suture before placement. After initial placement of leads and before the leads were 
secured to the tissue, base impedance was optimized by repositioning the leads, and the impedance value was verified 
by monitoring a live respiratory signal using DSI hardware and software. The depth of breathing was verified to 
ensure signal quality. 
Physiological Responses. Four freely moving monkeys implanted with the D70PCTR telemetry transmitter were 
used to evaluate the effects of BU08028 and MOP receptor agonists on physiological parameters. Respiration, blood 
pressure, ECG, and temperature were measured and analyzed with Ponemah version 5.2 (Data Sciences 
International). For acute drug effects, data from the 30-min interval before drug administration were collected as 
baseline and then at each time point (i.e., 1, 6, 24, and 48 h) after drug administration. For detecting precipitated 
withdrawal signs, data from the 30-min duration before administration of antagonist werecollected and then 
continuously for 2 h after antagonist administration. The mean value of each 15-min time block was generated from 
each subject to represent the measure outcomefor each single data point. 
Data Analysis. Mean ± SEM values were calculated from individual-subject data for all behavioral endpoints. 
Comparisons were made for the same monkeys across all test sessions in the same experiment. All data except 
selfadministration data were analyzed by repeated-measures two-way ANOVA, followed by Bonferroni’s multiple-
comparisons test. For each drug used in the self-administration paradigm, repeated-measures one-way ANOVA was 
conducted with the post hoc Dunnett’s test to determine which doses functioned as reinforcers. In addition, maximum 
reinforcing strength, defined as the peak number of reinforcers that a monkey earned regardless of dose, was 
compared across drugs using repeated-measures one-way ANOVA and a Holm–Sidak multiple-comparisons test. 
The criterion for significance for all tests was set at P < 0.05. To analyze nociceptive responses, individual tail-
withdrawal latencies were converted to the percentage of maximum possible effect. The formula for calculating the 
percentage of maximum possible effect was as follows: [(test latency ‒ control latency)/(cutoff latency, 20 s ‒ control 
latency)] × 100. 
Drugs. BU08028 HCl (37) (University of Bath) was dissolved in a solution of dimethyl sulfoxide/10% (mass/vol) 
(2-hydroxypropyl)-β-cyclodextrin in a ratio of 3:97. Morphine sulfate, buprenorphine HCl, fentanyl HCl, 
remifentanil HCl, and naltrexone HCl (National Institute on Drug Abuse) were dissolved in sterile water. The (‒
)cocaine HCl (National Institute on Drug Abuse) was dissolved in sterile 0.9% saline. J-113397 and SCH221510 
(Tocris Bioscience) were dissolved in a solution of dimethyl sulfoxide/Tween 80/sterile water in a ratio of 1:1:8. 
Capsaicin (Sigma-Aldrich) was dissolved in 70% (vol/vol) ethanol. For systemic administration, drugs were 
administered at a volume of 0.1 mL/kg. There was a minimum 1-wk interval between drug administrations. 
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Fig. 1. Effects of systemic administration of BU08028 on modulating sensory processing in monkeys. (A) 
Antinociception against acute noxious stimulus (50 °C water). (B) Antihypersensitivity against capsaicin-induced 
allodynia (46 °C water). (C) Effects of MOP receptor antagonist naltrexone (0.03 mg/kg) and NOP receptor antagonist 
J-113397 (0.1 mg/kg) on BU08028-induced antinociception. (D) Comparison of the antinociceptive potency of 
BU08028 and buprenorphine. (E) Comparison of antinociceptive duration of BU08028 (0.01 mg/kg) and 
buprenorphine (0.1 mg/kg). (F) Comparison of the itch scratching responses elicited by BU08028 (0.01 mg/kg) and 
fentanyl (0.018 mg/kg) at antinociceptive doses. Each data point represents mean ± SEM (n = 4). All drugs were 
delivered by the s.c. route. *P < 0.05, a significant difference from the vehicle condition from the first time point to 
the corresponding time point. 
 
 
  
  
 
Fig. 2. Reinforcing effects of cocaine, remifentanil, buprenorphine, and BU08028 in monkeys. (A) Number of 
injections received as a function of dose in monkeys responding under a PR schedule of reinforcement. (B) Peak 
injections received for each drug. Each data point represents mean ± SEM (n = 4). *P < 0.05, a significant difference 
from saline in both A and B. #P < 0.05, a significant difference between drugs in B 
  
  
Fig. 3. Effects of systemic administration of BU08028 on respiratory parameters of freely moving monkeys implanted 
with telemetric probes. (A) Respiration rate. (Inset) Fentanyl (0.056 mg/kg)-induced decreases in respiration rate that 
were reversed by naltrexone (0.7 mg/kg) administration. (B) Minute volume. (C) Tidal volume. (D) Peak inspiratory 
flow. (E) Peak expiratory flow. Each data point represents mean ± SEM (n = 4) from each individual data value 
averaged from a 15-min time block. All drugs were delivered by the i.m. route. Open symbols represent baselines of 
different dosing conditions for the same monkeys before drug administration. 
  
  
 
Fig. 4. Effects of systemic administration of BU08028 on cardiovascular parameters of freely moving monkeys 
implanted with telemetric probes. (A) Heart rate. (B) QRS interval. (C) ST-E (ST elevation). (D) Mean arterial pressure. 
(E) Pulse height. (F) Body temperature. Each data point represents mean ± SEM (n = 4) from each individual data value 
averaged from a 15-min time block. All drugs were delivered by the i.m. route. Open symbols represent baselines of 
different dosing conditions for the same monkeys before drug administration. 
  
  
 
 
Fig. 5. Comparison of precipitated withdrawal signs in monkeys from short-term repeated administration of 
morphine, SCH221510, or BU08028. Morphine (1.8 mg/kg) and SCH221510 (0.01 mg/kg) were administered twice 
daily for 3 d. Owing to its long duration, BU08028 (0.01 mg/kg) was administered once daily for 3 d. The antagonist 
naltrexone (0.01 mg/kg) or J-113397 (0.03 mg/kg) was used to precipitate withdrawal signs on day 4 for morphine-
treated subjects (A– E) or SCH221510-treated subjects (F–J). Both antagonists, naltrexone (0.01 mg/kg) and J-113397 
(0.03 mg/kg), were used to precipitate withdrawal signs on day 5 for BU08028-treated subjects (K–O). Antagonist-
precipitated withdrawal signs were measured in monkeys implanted with telemetric probes before and after 
antagonist treatment. (A, F, and K) Respiration rate. (B, G, and L) Minute volume. (C, H, and M) Heart rate. (D, I, and 
N) Mean arterial pressure. (E, J, and O) Body temperature. Data are shown as changes from baseline values (i.e., 
before antagonist treatment). Each data point represents mean ± SEM (n = 4) from each individual data value 
averaged from a 15-min time block. All drugs were delivered by the i.m. route. *P < 0.05, significantly different from 
vehicle from 15–30 min to the corresponding time point. 
 
 
